ZA200810850B - High affinity human and humanized anti-+-5²1 integrin function blocking antibodies with reduced immunogenicity - Google Patents

High affinity human and humanized anti-+-5²1 integrin function blocking antibodies with reduced immunogenicity

Info

Publication number
ZA200810850B
ZA200810850B ZA200810850A ZA200810850A ZA200810850B ZA 200810850 B ZA200810850 B ZA 200810850B ZA 200810850 A ZA200810850 A ZA 200810850A ZA 200810850 A ZA200810850 A ZA 200810850A ZA 200810850 B ZA200810850 B ZA 200810850B
Authority
ZA
South Africa
Prior art keywords
high affinity
humanized anti
reduced immunogenicity
blocking antibodies
affinity human
Prior art date
Application number
ZA200810850A
Other languages
English (en)
Inventor
Andreas Menrad
Joerg Willuda
Klaus Bosslet
Dieter Zopft
Heike Petrul
Stefan Steidl
Josef Prassler
Corinne Petit-Frere
Original Assignee
Bayer Schering Pharma Ag
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag, Morphosys Ag filed Critical Bayer Schering Pharma Ag
Publication of ZA200810850B publication Critical patent/ZA200810850B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
ZA200810850A 2006-05-24 2008-12-23 High affinity human and humanized anti-+-5²1 integrin function blocking antibodies with reduced immunogenicity ZA200810850B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06010779 2006-05-24

Publications (1)

Publication Number Publication Date
ZA200810850B true ZA200810850B (en) 2010-05-26

Family

ID=38659612

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200810850A ZA200810850B (en) 2006-05-24 2008-12-23 High affinity human and humanized anti-+-5²1 integrin function blocking antibodies with reduced immunogenicity

Country Status (23)

Country Link
US (1) US20090081207A1 (xx)
EP (1) EP2032605A2 (xx)
JP (1) JP2009537158A (xx)
KR (1) KR20090027218A (xx)
CN (1) CN101495515A (xx)
AR (1) AR061107A1 (xx)
AU (1) AU2007253586A1 (xx)
BR (1) BRPI0711796A2 (xx)
CA (1) CA2652886A1 (xx)
CL (1) CL2007001488A1 (xx)
CR (1) CR10456A (xx)
DO (2) DOP2007000101A (xx)
EA (1) EA200802348A1 (xx)
EC (1) ECSP088909A (xx)
MA (1) MA30425B1 (xx)
MX (1) MX2008014910A (xx)
NO (1) NO20085362L (xx)
PE (1) PE20080100A1 (xx)
TN (1) TNSN08469A1 (xx)
TW (1) TW200817433A (xx)
UY (1) UY30362A1 (xx)
WO (1) WO2007134876A2 (xx)
ZA (1) ZA200810850B (xx)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
ES2547421T3 (es) 2005-10-31 2015-10-06 Oncomed Pharmaceuticals, Inc. Composiciones y métodos para diagnosticar y tratar el cáncer
MY159375A (en) 2006-03-21 2016-12-30 Genentech Inc Combinatorial therapy
US7973138B2 (en) 2007-09-26 2011-07-05 Genentech, Inc. Antibodies
CA2714071A1 (en) * 2008-02-05 2009-08-13 Bristol-Myers Squibb Company Alpha 5 - beta 1 antibodies and their uses
NZ592338A (en) 2008-09-26 2012-11-30 Oncomed Pharm Inc Frizzled-binding agents and uses thereof
AU2009313389A1 (en) * 2008-11-06 2010-05-14 Alexion Pharmaceuticals, Inc. Engineered antibodies with reduced immunogenicity and methods of making
AU2009331528A1 (en) * 2008-12-23 2011-08-11 Astrazeneca Ab Targeted binding agents directed to alpha5beta1 and uses thereof
EP2411411B1 (en) 2009-03-25 2016-08-31 F.Hoffmann-La Roche Ag Novel anti-alpha5beta1 antibodies and uses thereof
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
AU2011235904B2 (en) 2010-04-01 2015-10-08 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
EP2933262B1 (en) * 2010-07-09 2018-05-02 Affibody AB Polypeptides
UY33337A (es) 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
EP2545905A1 (en) 2011-07-11 2013-01-16 Britannia Pharmaceuticals Limited A new therapeutical composition containing apomorphine as active ingredient
TWI586378B (zh) 2012-03-13 2017-06-11 瑞斯比維特有限公司 新穎醫藥調配物
US9266959B2 (en) 2012-10-23 2016-02-23 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using frizzled-binding agents
AU2013370467B2 (en) * 2012-12-26 2018-10-04 Oncosynergy, Inc. Anti- integrin beta1 antibody compositions and methods of use thereof
US9359444B2 (en) 2013-02-04 2016-06-07 Oncomed Pharmaceuticals Inc. Methods and monitoring of treatment with a Wnt pathway inhibitor
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
KR20180012832A (ko) * 2015-06-28 2018-02-06 올제네시스 바이오테라퓨틱스 아이엔씨. 혈관신생 억제용 융합 단백질
WO2021015336A1 (ko) * 2019-07-24 2021-01-28 가톨릭대학교 산학협력단 αVβ3 인테그린 표적 단일 도메인 항체
US11723955B1 (en) 2022-05-13 2023-08-15 Allgenesis Biotherapeutics Inc. VEGFR fusion protein pharmaceutical composition

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013495A (en) * 1994-10-21 2000-01-11 The Scripps Research Institute Methods of use for integrin B1C cell growth inhibitor
US6852318B1 (en) * 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
US7285268B2 (en) * 2002-11-26 2007-10-23 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
US7276589B2 (en) * 2002-11-26 2007-10-02 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
KR20110140143A (ko) * 2002-11-26 2011-12-30 애보트 바이오테라퓨틱스 코포레이션 혈관형성을 조절하는 α5β1 인테그린에 대한 키메라성 및 인간화 항체
EP1755659B1 (en) * 2004-03-24 2011-11-02 Abbott Biotherapeutics Corp. Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation
MY159375A (en) * 2006-03-21 2016-12-30 Genentech Inc Combinatorial therapy

Also Published As

Publication number Publication date
MA30425B1 (fr) 2009-05-04
DOP20070101A (es) 2007-12-30
TNSN08469A1 (en) 2010-04-14
WO2007134876A3 (en) 2008-03-27
KR20090027218A (ko) 2009-03-16
MX2008014910A (es) 2009-01-23
BRPI0711796A2 (pt) 2011-12-06
ECSP088909A (es) 2008-12-30
EA200802348A1 (ru) 2009-08-28
WO2007134876A2 (en) 2007-11-29
TW200817433A (en) 2008-04-16
AU2007253586A1 (en) 2007-11-29
US20090081207A1 (en) 2009-03-26
EP2032605A2 (en) 2009-03-11
PE20080100A1 (es) 2008-04-18
UY30362A1 (es) 2008-01-02
JP2009537158A (ja) 2009-10-29
CA2652886A1 (en) 2007-11-29
WO2007134876A8 (en) 2009-07-02
NO20085362L (no) 2009-02-23
DOP2007000101A (es) 2007-12-31
CL2007001488A1 (es) 2008-01-04
AR061107A1 (es) 2008-08-06
CN101495515A (zh) 2009-07-29
CR10456A (es) 2009-02-26

Similar Documents

Publication Publication Date Title
ZA200810850B (en) High affinity human and humanized anti-+-5²1 integrin function blocking antibodies with reduced immunogenicity
HRP20181969T1 (hr) Humanizirana protutijela protiv čimbenika d i njihova upotreba
IL240245A0 (en) Antibodies against 5t4 and their uses
HK1208228A1 (en) Antibodies and immunoconjugates and uses therefor
IL200610A0 (en) Human monoclonal anti-ip-10 antibodies and uses thereof
AP2809A (en) Anti-Alpha2 Integrin antibodies and their uses
HK1182721A1 (zh) 抗體和免疫偶聯物及其用途
IL194266A0 (en) Anti-igf-ir antibodies and uses thereof
IL193922A0 (en) Anti-tat226 antibodies and immunoconjugates
ZA201001260B (en) Immunogenic polypeptides and monoclonal antibodies
EP2077325A4 (en) MONOCLONAL ANTIBODY AND ITS USE